One may ask whether early-onset cancer in your family is caused by a hereditary condition such as Li-Fraumeni Syndrome (LFS). You are not alone. Genetic testing is fortunately accessible, and being aware of your status can save your life. We'll take you step-by-step through the process of getting tested for LFS and explaining the true meaning of your results.
What is li-fraumeni syndrome?
Li-Fraumeni Syndrome (LFS) is a rare hereditary condition caused by mutations in the TP53 tumour suppressor gene. It raises the lifetime risk of some malignancies considerably, such as:
- Breast cancer
- Soft tissue sarcomas
- Osteosarcoma
- Brain tumors
- Adrenocortical carcinoma
- Leukaemia and others
Cancer frequently strikes people with LFS at an early age, and they may have several tumours in their lives. With an autosomal dominant inheritance pattern, there is a 50% chance that the syndrome will be passed on to offspring.1,2,3
Who should get the test done?
If you or a family member fits any of the following Chompret Criteria, testing is recommended:
- Early-onset breast cancer (before age 31)
- Personal or family history of LFS-related cancers
- Multiple primary tumors
- Adrenocortical carcinoma or choroid plexus tumors at any age4
How to get tested for li-fraumeni syndrome?
Step 1: Genetic guidance
Consultation with a genetic counsellor is essential before any testing. Your personal and family medical history will be reviewed, your risk factors will be evaluated, and the counsellor will explain the TP53 genetic test during this session. This discussion makes sure you comprehend the results' possible consequences, emotional toll, and medical consequences. In order to have informed consent and get psychologically ready for the procedure, this phase is essential.5
Step 2: Genetic test for TP53
A blood sample or saliva sample is usually used for the actual TP53 genetic test. A lab analyses your DNA after it has been collected to look for any known abnormalities in the TP53 gene, which is connected to a number of hereditary cancer disorders, including Li-Fraumeni syndrome. If certain medical or family history requirements are satisfied, many insurance companies may pay for this test, which typically costs between $300 and $1,000. Although this timeframe can vary based on the lab and the intricacy of the results, results are typically available 2–4 weeks after the sample is processed.6
Step 3: Post-test counselling
You will see your genetic counsellor or a medical specialist again when your results are available. Along with discussing the best course of action, they will assist in interpreting the results and their implications for your health. This can entail educating family members who are at risk, conducting additional tests, or taking preventative action. Counselling after the test guarantees that you fully comprehend your findings and get the assistance you need to decide on your next course of treatment.7
What do the results mean?
A positive TP53 mutation test indicates that you have Li-Fraumeni Syndrome (LFS), a genetic disorder linked to a markedly elevated chance of acquiring a variety of malignancies, with a lifetime cancer risk that can reach 70–100% for some types. Due to this increased risk, your healthcare team will probably advise routine cancer screening, which might involve yearly whole-body MRIs, breast MRIs starting at age 20, and colonoscopies starting at age 25. To determine their risk, family members should also be allowed to undergo genetic testing.8
Your risk is lowered if your test is negative, meaning no TP53 mutation was discovered; nevertheless, this does not rule out a hereditary cancer syndrome, particularly if you have a significant family history. As science and testing capabilities advance, your healthcare professional might still advise continued monitoring or future retesting.9
A genetic alteration has been discovered in situations where a Variant of Uncertain Significance (VUS) has been identified, although it is still unclear if this alteration results in disease. Your doctor may advise ongoing monitoring until further research is done to determine the relevance of the variant, even though a VUS by itself won't be used to diagnose LFS.10
Living with a positive result
To create a customised cancer screening plan based on your unique risks, it's critical to collaborate closely with an oncologist or geneticist if you test positive for a TP53 mutation. Risk-reducing procedures, such as mastectomy or hysterectomy (for women), may be taken into consideration in some situations to reduce the likelihood of acquiring specific cancers.
Radiation exposure should be avoided wherever feasible, particularly during diagnostic imaging and therapy, as TP53 mutations are linked to increased sensitivity to radiation. Furthermore, it becomes essential to provide genetic testing to family members in order to discover additional individuals who might possibly possess the mutation and benefit from early monitoring or treatment.11
What are the psychological impacts of testing?
Getting the results of a DNA test can cause a range of emotions; some people may feel anxious, afraid, or uncertain, while many others are happy to finally have answers. Pre- and post-test genetic counselling is crucial for this reason and should never be disregarded. In addition to helping you navigate difficult medical decisions, counselling offers emotional support and helps you comprehend the ramifications of your findings. According to research, people who undergo counselling report less long-term distress and make better decisions on lifestyle choices, screening, and preventative measures.12
Summary
A rare hereditary disorder called Li-Fraumeni Syndrome (LFS) is brought on by mutations in the TP53 gene and dramatically raises the lifelong chance of developing several cancers, including leukaemia, brain tumours, sarcomas, and breast cancer. It has a 50% chance of being passed on to offspring since it follows an autosomal dominant inheritance pattern. If you or a family member has several primary tumours or early-onset cancer, for example, genetic testing is advised.
The TP53 genetic test (by blood or saliva), post-test genetic counselling, and pre-test genetic counselling are the three main components of testing. Through counselling, patients can better comprehend their risk, emotionally prepare, and make wise decisions. If the test is positive, LFS is confirmed, and risk-reducing operations and close cancer monitoring are necessary. Radiation should be avoided due to the heightened sensitivity. Negative results reduce risk but do not completely rule out a hereditary syndrome; a Variant of Uncertain Significance (VUS) indicates that additional information is required to evaluate risk.
Working closely with professionals for individualised care and promoting family testing for early discovery are essential for those living with a TP53 mutation. Genetic counselling is crucial since testing can either be emotionally taxing or reassuring. Counselling reduces long-term distress and improves decision-making on screening, prevention, and lifestyle modifications, according to studies.
FAQs
Can the TP53 test be performed at home?
No, you cannot do the TP53 test at home. It is a genetic test that looks for mutations in the TP53 gene. Usually, a healthcare provider must draw a sample of blood or tissue, which is subsequently sent to a lab for examination.13
How does li-fraumeni vary from hereditary breast cancer (BRCA)?
Although they involve different genes and cancer profiles, both raise the risk of developing cancer. TP53 mutations begin earlier and impact a wider variety of malignancies. Early onset and a wider variety of malignancies are impacted by TP53 mutations.14
Can a person with a TP53 mutation avoid developing cancer?
No, a TP53 mutation does not prevent cancer from occurring in a person. The chance of getting breast, brain, sarcoma, and other cancers is greatly increased by TP53 mutations, especially when they are hereditary.15
References
- Aedma SK, Kasi A. Li-Fraumeni Syndrome [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532286/
- Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. Journal of Clinical Oncology [Internet]. 2015 May 27;33(21):2345–52. Available from: https://pubmed.ncbi.nlm.nih.gov/26014290/
- Bradbury AR, Patrick‐Miller L, Egleston BL, Olopade OI, Daly MB, Moore CW, et al. When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response. Cancer [Internet]. 2012 Jan 9;118(13):3417–25. Available from: https://doi.org/10.1002/cncr.26471
- Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, et al. Sensitivity and predictive value of criteria for p53germline mutation screening. Journal of Medical Genetics [Internet]. 2001 Jan 1;38(1):43–7. Available from: https://pubmed.ncbi.nlm.nih.gov/11332399/
- Counseling about Cancer: Strategies for Genetic Counseling, 4th edition. Wiley.com. Available from: https://www.wiley.com/en-us/Counseling+About+Cancer%3A+Strategies+for+Genetic+Counseling%2C+4th+Edition-p-9781119466475
- DePolo J. Types of genetic tests [Internet]. 2024. Available from: https://www.breastcancer.org/genetic-testing/types-of-tests#
- Genetic test for Li-Fraumeni Syndrome by Ambry Genetics | Ambry Genetics. Available from: https://www.ambrygen.com/providers/genetic-testing/81/neurology/li-fraumeni-syndrome
- Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. Journal of Medical Genetics [Internet]. 2009 Jun 25;46(10):689–93. Available from: https://pubmed.ncbi.nlm.nih.gov/19556618/
- Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine [Internet]. 2014 Nov 13;17(1):70–87. Available from: https://doi.org/10.1038/gim.2014.147
- Himes DO, Shuman HB. Hereditary Cancer Syndrome recognition and Testing: Beyond BRCA. The Journal for Nurse Practitioners [Internet]. 2020 May 4;16(7):517–22. Available from: https://doi.org/10.1016/j.nurpra.2020.03.015
- Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort. Cancer [Internet]. 2016 Aug 6;122(23):3673–81. Available from: https://doi.org/10.1002/cncr.30248
- Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms. Science [Internet]. 1990 Nov 30;250(4985):1233–8. Available from: https://pubmed.ncbi.nlm.nih.gov/1978757/
- Rare TP53 gene mutation linked to risk for multiple cancers | Penn Medicine. Penn Medicine [Internet]. 2020 Jul 16; Available from: https://www.pennmedicine.org/news/rare-mutation-of-tp53-gene-leaves-people-at-higher-risk-for-multiple-cancers
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine [Internet]. 2015 Mar 5;17(5):405–24. Available from: https://doi.org/10.1038/gim.2015.30
- Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR, et al. Somatic TP53 variants frequently confound germ-line testing results. Genetics in Medicine [Internet]. 2017 Nov 30;20(8):809–16. Available from: https://doi.org/10.1038/gim.2017.196

